# US 2019/0169617 A1 · Pharmaceutical composition for treating and/or preventing cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0169617 A1 - Document ID: US20190169617A1 - Status: Published application - Kind: A1 - Application number: 16/321,260 - Filed: 2017-08-09 - Published: 2019-06-06 - Earliest claimed: 2016-08-09 - Assignees: Toray Industries, Inc. - Applicants: Toray Industries, Inc. - Inventors: Atsuko MIYANO; Aiko TAKAYAMA; Hiroko SUDO; Taiga ARAI - Web page: https://patentgrep.com/patent/US20190169617A1 ## CPC - C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} - A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links - A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy - A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct} - A61P 35/00: Antineoplastic agents - C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract It is an object of the present invention to specify miRNA associated with the treatment and/or prevention of various cancer species, from among various miRNAs associated with cancer, and to provide a novel pharmaceutical composition for treating and/or preventing cancer which targets the specified miRNA. According to the present invention, provided are a pharmaceutical composition for treating and/or preventing cancer comprising, as an active ingredient, an antisense polynucleotide shown as hsa-miR4454, a combination drug comprising the aforementioned pharmaceutical composition and another antitumor agent, and a method for treating and/or preventing cancer, using the above-described pharmaceutical composition or combination drug. ## Claims ### Claim 1 A pharmaceutical composition for treating and/or preventing cancer comprising, as an active ingredient, the antisense polynucleotide of microRNA shown as hsa-miR4454. ### Claim 2 (depends on 1) The pharmaceutical composition for treating and/or preventing cancer according to claim 1, wherein the antisense polynucleotide is RNA or DNA. ### Claim 3 (depends on 1) The pharmaceutical composition for treating and/or preventing cancer according to claim 1, wherein the antisense polynucleotide comprises a nucleotide sequence having a sequence identity of 90% or more to a nucleotide sequence complementary to the nucleotide sequence as set forth in SEQ ID NO: 1. ### Claim 4 (depends on 1) The pharmaceutical composition for treating and/or preventing cancer according to claim 1, wherein the nucleotide sequence length of the antisense polynucleotide consists of 8 to 60 nucleotides. ### Claim 5 (depends on 1) The pharmaceutical composition for treating and/or preventing cancer according to claim 1, wherein the antisense polynucleotide consists of the nucleotide sequence as set forth in SEQ ID NO: 2 or 3. ### Claim 6 (depends on 1) The pharmaceutical composition for treating and/or preventing cancer according to claim 1, wherein the cancer expresses hsa-miR4454. ### Claim 7 (depends on 1) The pharmaceutical composition for treating and/or preventing cancer according to claim 1, wherein the cancer is colorectal cancer, breast cancer, lung cancer, liver cancer, pancreatic cancer, blood cancer, kidney cancer, brain tumors, stomach cancer, cervical cancer, ovarian cancer, prostate cancer, bladder cancer, esophagus cancer, fibrosarcomas, mast cell tumors, or melanomas. ### Claim 8 (depends on 1) The pharmaceutical composition for treating and/or preventing cancer according to claim 1, wherein the antisense polynucleotide is inserted into a vector, so that it can be expressed in the form of RNA or DNA. ### Claim 9 (depends on 1) The pharmaceutical composition for treating and/or preventing cancer according to claim 1, wherein the antisense polynucleotide is encapsulated into a carrier selected from the group consisting of non-cationic polymer carriers, liposome carriers, dendritic carriers, nano-material carriers, microparticle carriers, biostructural carriers, micelle carriers, polymer microparticles, and magnetic microparticles. ### Claim 10 (depends on 1) A combination drug for treating and/or preventing cancer comprising, as active ingredients, the pharmaceutical composition for treating and/or preventing cancer according to claim 1, and an antitumor agent. ### Claim 11 (depends on 1) A method for treating and/or preventing cancer in a subject who suffers or has suffered from the cancer, comprising administering the pharmaceutical composition according to claim 1.